342 results on '"P. Borchmann"'
Search Results
2. Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
- Author
-
Driessen, Julia, de Wit, Fer, Herrera, Alex F., Zinzani, Pier Luigi, LaCasce, Ann S., Cole, Peter D., Moskowitz, Craig H., García-Sanz, Ramón, Fuchs, Michael, Müller, Horst, Borchmann, Peter, Santoro, Armando, Schöder, Heiko, Zijlstra, Josée M., Hutten, Barbara A., Moskowitz, Alison J., and Kersten, Marie José
- Abstract
•BV with or without chemotherapy does not increase CMR rates or PFS in R/R cHL but seems to increase PFS in patients with relapsed or stage IV disease.•Sequential treatment with BV and chemotherapy is feasible and could spare salvage chemotherapy in a subset of fast responding patients.
- Published
- 2024
- Full Text
- View/download PDF
3. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
- Author
-
Schorb, Elisabeth, Isbell, Lisa Kristina, Kerkhoff, Andrea, Mathas, Stephan, Braulke, Friederike, Egerer, Gerlinde, Röth, Alexander, Schliffke, Simon, Borchmann, Peter, Brunnberg, Uta, Kroschinsky, Frank, Möhle, Robert, Rank, Andreas, Wellnitz, Dominique, Kasenda, Benjamin, Pospiech, Lisa, Wendler, Julia, Scherer, Florian, Deckert, Martina, Henkes, Elina, von Gottberg, Philipp, Gmehlin, Dennis, Backenstraß, Matthias, Jensch, Antje, Burger-Martin, Elvira, Grishina, Olga, Fricker, Heidi, Malenica, Natalie, Orbán, András, Duyster, Justus, Ihorst, Gabriele, Finke, Juergen, and Illerhaus, Gerald
- Abstract
Available treatments for older patients with primary diffuse large B-cell CNS lymphoma (PCNSL) offer progression-free survival of up to 16 months. We aimed to investigate an intensified treatment of high-dose chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT) in older patients with PCNSL.
- Published
- 2024
- Full Text
- View/download PDF
4. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
- Author
-
Fuchs, Michael, Jacob, Anne Sophie, Kaul, Helen, Kobe, Carsten, Kuhnert, Georg, Pabst, Thomas, Greil, Richard, Bröckelmann, Paul J., Topp, Max S., Just, Marianne, Hertenstein, Bernd, Soekler, Martin, Vogelhuber, Martin, Zijlstra, Josée M., Keller, Ulrich Bernd, Krause, Stefan W., Dührsen, Ulrich, Meissner, Julia, Viardot, Andreas, Eich, Hans-Theodor, Baues, Christian, Diehl, Volker, Rosenwald, Andreas, Buehnen, Ina, von Tresckow, Bastian, Dietlein, Markus, Borchmann, Peter, Engert, Andreas, and Eichenauer, Dennis A.
- Abstract
The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18–75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2% after CMT (n= 328) and 86.7% after ABVD alone (n= 300; HR = 2.05 [1.20–3.51]; p= 0.0072). 5-year OS was 98.3% and 98.8%, respectively (p= 0.14); 4/12 documented deaths were caused by second primary malignancies and only one by HL. Among patients assigned to CMT, 5-year PFS was better in PET-2-negative (n= 353; 94.0%) than in PET-2-positive patients (n= 340; 90.3%; p= 0.012). The difference was more pronounced when using DS4 as cut-off (DS 1-3: n= 571; 94.0% vs. DS ≥ 4: n= 122; 83.6%; p< 0.0001). Taken together, CMT should be considered standard treatment for early-stage favorable HL irrespective of the PET-2-result.
- Published
- 2024
- Full Text
- View/download PDF
5. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
- Author
-
Morschhauser, Franck, Dahiya, Saurabh, Palomba, M. Lia, Martin Garcia-Sancho, Alejandro, Reguera Ortega, Juan Luis, Kuruvilla, John, Jäger, Ulrich, Cartron, Guillaume, Izutsu, Koji, Dreyling, Martin, Kahl, Brad, Ghesquieres, Hervé, Ardeshna, Kirit, Goto, Hideki, Barbui, Anna Maria, Abramson, Jeremy S., Borchmann, Peter, Fleury, Isabelle, Mielke, Stephan, Skarbnik, Alan, de Vos, Sven, Kamdar, Manali, Karmali, Reem, Viardot, Andreas, Farazi, Thalia, Fasan, Omotayo, Lymp, James, Vedal, Min, Nishii, Rina, Avilion, Ariel, Papuga, Jessica, Kumar, Jinender, and Nastoupil, Loretta J.
- Abstract
An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), due to no established standard of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two or more lines of prior systemic therapy, but there is no consensus on its optimal timing in the disease course of FL, and there are no data in second-line (2L) treatment of patients with high-risk features. Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB CAR T cell product. The phase 2 TRANSCEND FL study evaluated liso-cel in patients with R/R FL, including 2L patients who all had POD24 from diagnosis after treatment with anti-CD20 antibody and alkylator ≤6 months of FL diagnosis and/or met modified Groupe d’Etude des Lymphomes Folliculaires criteria. Primary/key secondary endpoints were independent review committee–assessed overall response rate (ORR)/complete response (CR) rate. At data cutoff, 130 patients had received liso-cel (median follow-up, 18.9 months). Primary/key secondary endpoints were met. In third-line or later FL (n= 101), ORR was 97% (95% confidence interval (CI): 91.6‒99.4), and CR rate was 94% (95% CI: 87.5‒97.8). In 2L FL (n= 23), ORR was 96% (95% CI: 78.1‒99.9); all responders achieved CR. Cytokine release syndrome occurred in 58% of patients (grade ≥3, 1%); neurological events occurred in 15% of patients (grade ≥3, 2%). Liso-cel demonstrated efficacy and safety in patients with R/R FL, including high-risk 2L FL. ClinicalTrials.gov identifier: NCT04245839.
- Published
- 2024
- Full Text
- View/download PDF
6. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
- Author
-
Mackensen, Andreas, Haanen, John B.A.G., Koenecke, Christian, Alsdorf, Winfried, Wagner-Drouet, Eva, Borchmann, Peter, Heudobler, Daniel, Ferstl, Barbara, Klobuch, Sebastian, Bokemeyer, Carsten, Desuki, Alexander, Lüke, Florian, Kutsch, Nadine, Müller, Fabian, Smit, Eveline, Hillemanns, Peter, Karagiannis, Panagiotis, Wiegert, Erol, He, Ying, Ho, Thang, Kang-Fortner, Qing, Schlitter, Anna Melissa, Schulz-Eying, Catrine, Finlayson, Andrew, Flemmig, Carina, Kühlcke, Klaus, Preußner, Liane, Rengstl, Benjamin, Türeci, Özlem, and Şahin, Uğur
- Abstract
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, and could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating the safety and feasibility of chimeric antigen receptor (CAR) T cells targeting the CLDN6 with or without a CAR-T cell-amplifying RNA vaccine (CARVac) at two dose levels (DLs) in relapsed/refractory CLDN6-positive solid tumors. The primary endpoints were safety and tolerability, maximum tolerated dose and recommended phase 2 dose (RP2D). Secondary endpoints included objective response rate (ORR) and disease control rate. We observed manageable toxicity, with 10 out of 22 patients (46%) experiencing cytokine release syndrome including one grade 3 event and 1 out of 22 (5%) with grade 1 immune effector cell-associated neurotoxicity syndrome. Dose-limiting toxicities occurred in two patients at the higher DL, resolving without sequelae. CAR-T cell engraftment was robust, and the addition of CARVac was well tolerated. The unconfirmed ORR in 21 evaluable patients was 33% (7 of 21), including one complete response. The disease control rate was 67% (14 of 21), with stable disease in seven patients. Patients with germ cell tumors treated at the higher DL exhibited the highest response rate (ORR 57% (4 of 7)). The maximum tolerated dose and RP2D were not established as the trial has been amended to utilize an automated manufacturing process. A repeat of the dose escalation is ongoing and will identify a RP2D for pivotal trials. ClinicalTrials.gov Identifier: NCT04503278.
- Published
- 2023
- Full Text
- View/download PDF
7. Erste S3-Leitlinie zum diffusen großzelligen B-Zell-Lymphom und zu verwandten Entitäten
- Author
-
Ernst, Moritz, Skoetz, Nicole, and Borchmann, Peter
- Published
- 2023
- Full Text
- View/download PDF
8. Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
- Author
-
Eichenauer, Dennis A., Bühnen, Ina, Baues, Christian, Kobe, Carsten, Kaul, Helen, Greil, Richard, Moccia, Alden, Zijlstra, Joseé M., Hertenstein, Bernd, Topp, Max S., Just, Marianne, von Tresckow, Bastian, Eich, Hans-Theodor, Fuchs, Michael, Dietlein, Markus, Hartmann, Sylvia, Engert, Andreas, and Borchmann, Peter
- Abstract
•In early-stage favorable NLPHL, consolidation RT appears necessary to achieve the optimal disease control irrespective of the iPET result.•In early-stage NLPHL, Hodgkin lymphoma–directed approaches result in a 5-year PFS >90% and a 5-year overall survival of 100%.
- Published
- 2023
- Full Text
- View/download PDF
9. FDG-Positronenemissionstomographie-Computertomographie und neue Chancen zur Therapiesteuerung
- Author
-
Kobe, Carsten, Baues, Christian, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Eich, Hans-Theodor, and Dietlein, Markus
- Abstract
Hintergrund: Die Nutzung der Positronenemissionstomographie-Computertomographie mit
18 F‑Fluordesoxyglukose (FDG-PET-CT) vor, während und nach Abschluss der Chemotherapie wurde untersucht, um die Behandlungsintensität beim Hodgkin-Lymphom zu optimieren. Ziel: FDG-PET-CT-adaptierte Therapiekonzepte wurden von der German Hodgkin Study Group (GHSG) in den Multizenterstudien HD15, HD16, HD17 und HD18 erprobt. Die HD15-Studie untersuchte den Verzicht auf eine Strahlentherapie bei FDG-PET-CT-negativem Restgewebe für fortgeschrittene Stadien. Die HD16-Studie untersuchte eine vergleichbare Fragestellung für frühe und die HD17-Studie intermediäre Stadien. In HD18 wurde bei PET-negativen Patienten nach 2 Zyklen Chemotherapie die Möglichkeit der Reduktion der Anzahl der Chemotherapiezyklen geprüft. Stadienübergreifend wurde anhand der Daten aus HD16, HD17 und HD18 der Einsatz der FDG-PET-CT im initialen Staging analysiert. Ergebnisse: Die Therapiestratifizierung mittels FDG-PET-CT nach Abschluss der Chemotherapie ist sowohl im fortgeschrittenen Stadien des Hodgkin-Lymphoms als auch im intermediären Stadium gesichert. Auch erlaubt die FDG-PET-CT nach 2 Zyklen Chemotherapie in fortgeschrittenen Stadien eine Reduktion der Anzahl applizierter Chemotherapie. Im Staging vor Therapiebeginn ist die FDG-PET-CT nicht zuletzt wegen des dadurch möglichen Verzichts auf die Knochenmarkbiopsie heute Standard. Der Verzicht auf eine Strahlentherapie nach einer weniger intensiven Chemotherapie in frühen Stadien des Hodgkin-Lymphoms ist hingegen nicht zum Standard geworden. Schlussfolgerung: Die FDG-PET-CT ist heute Standard im Staging vor, während und nach Chemotherapie des Hodgkin-Lymphoms.- Published
- 2022
- Full Text
- View/download PDF
10. Clinical applications of circulating tumor DNA in Hodgkin lymphoma
- Author
-
Heger, Jan-Michel, Ferdinandus, Justin, Mattlener, Julia, and Borchmann, Sven
- Abstract
Hodgkin lymphoma is a B-cell lymphoma often affecting young adults. Outcomes following intensive chemo- and radiotherapy are generally favourable but leave patients at high risk for early and late toxicities frequently reducing quality of life. Relapsed/refractory disease is regularly difficult to treat and ultimately results in death in a relevant subset of patients. Current strategies for risk stratification and response evaluation rely on clinical features and imaging only, and lack discriminatory power to detect patients at risk for disease progression. Here, we explore how circulating tumor DNA sequencing might help to overcome these shortcomings. We provide an overview over recent technical and methodological developments and suggest potential use cases for different clinical situations. Circulating tumor DNA sequencing offers the potential to significantly augment current risk stratification strategies with the ultimate goal of further individualizing treatment strategies for patients with HL.
- Published
- 2023
- Full Text
- View/download PDF
11. Moderne Radiotherapie beim Hodgkin-Lymphom
- Author
-
Oertel, Michael, Baues, Christian, Fuchs, Michael, Pepper, Niklas Benedikt, Steike, David Rene, Borchmann, Peter, and Eich, Hans Theodor
- Abstract
Hintergrund: Die Radiotherapie ist ein integraler Bestandteil der Behandlung des Hodgkin-Lymphoms in den frühen Stadien. Angesichts der sehr guten Langzeitprognose ist die zusätzliche (Radio‑)Therapie gegenüber potenziellen (Langzeit‑)Toxizitäten kritisch abzuwägen, sodass eine individualisierte Risikoanalyse sinnvoll erscheint. Material und Methoden: Im November 2022 erfolgte eine selektive Literaturrecherche zur Radiotherapie mediastinaler Lymphome mit Fokus auf Bestrahlungstechniken und -konzepten. Hierbei wurden die Erfahrungen der German Hodgkin Study Group sowie anderer Studiengruppen zusammengefasst. Ergebnisse: Das aktuelle Bestrahlungskonzept ist die Involved-Node- bzw. Involved-Site-Radiotherapie, die eine Individualisierung der Bestrahlungsfelder ermöglicht. Bei der Behandlung des Mediastinums ist die Durchführung in tiefer Inspiration sinnvoll. Eine generelle Empfehlung für eine definierte Bestrahlungstechnik existiert nicht; diese sollte durch Vergleichsplanung ermittelt werden. Dosimetrische Analysen zeigen die insgesamt niedrige Exposition thorakaler Risikoorgane auf, die jedoch je nach Befallsmuster des Lymphoms stark variieren kann. Diskussion: Schon jetzt existieren mögliche Strategien der Individualisierung der Bestrahlungsplanung, die situations- und patientenadaptiert eingesetzt werden sollten. Weitere Entwicklungen mittels künstlicher Intelligenz und gepoolter Datenbankanalysen können helfen, die Risikoabschätzung weiterzuentwickeln.
- Published
- 2023
- Full Text
- View/download PDF
12. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
- Author
-
Nanni, Cristina, Kobe, Carsten, Baeßler, Bettina, Baues, Christian, Boellaard, Ronald, Borchmann, Peter, Buck, Andreas, Buvat, Irène, Chapuy, Björn, Cheson, Bruce D, Chrzan, Robert, Cottereau, Ann-Segolene, Dührsen, Ulrich, Eikenes, Live, Hutchings, Martin, Jurczak, Wojciech, Kraeber-Bodéré, Françoise, Lopci, Egesta, Luminari, Stefano, MacLennan, Steven, Mikhaeel, N George, Nijland, Marcel, Rodríguez-Otero, Paula, Treglia, Giorgio, Withofs, Nadia, Zamagni, Elena, Zinzani, Pier Luigi, Zijlstra, Josée M, Herrmann, Ken, and Kunikowska, Jolanta
- Abstract
Given the paucity of high-certainty evidence, and differences in opinion on the use of nuclear medicine for hematological malignancies, we embarked on a consensus process involving key experts in this area. We aimed to assess consensus within a panel of experts on issues related to patient eligibility, imaging techniques, staging and response assessment, follow-up, and treatment decision-making, and to provide interim guidance by our expert consensus. We used a three-stage consensus process. First, we systematically reviewed and appraised the quality of existing evidence. Second, we generated a list of 153 statements based on the literature review to be agreed or disagreed with, with an additional statement added after the first round. Third, the 154 statements were scored by a panel of 26 experts purposively sampled from authors of published research on haematological tumours on a 1 (strongly disagree) to 9 (strongly agree) Likert scale in a two-round electronic Delphi review. The RAND and University of California Los Angeles appropriateness method was used for analysis. Between one and 14 systematic reviews were identified on each topic. All were rated as low to moderate quality. After two rounds of voting, there was consensus on 139 (90%) of 154 of the statements. There was consensus on most statements concerning the use of PET in non-Hodgkin and Hodgkin lymphoma. In multiple myeloma, more studies are required to define the optimal sequence for treatment assessment. Furthermore, nuclear medicine physicians and haematologists are awaiting consistent literature to introduce volumetric parameters, artificial intelligence, machine learning, and radiomics into routine practice.
- Published
- 2023
- Full Text
- View/download PDF
13. Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis
- Author
-
Borchmann, Peter, Heger, Jan-Michel, Mahlich, Jörg, Papadimitrious, Michael S., Riou, Sybille, and Werner, Barbara
- Abstract
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma with increasing prevalence.Although the disease burden associated with DLBCL is high, only limited data on healthcare resource utilization (HCRU) and associated costs of German patients with DLBCL is available. Methods: Using a large claims database of the German statutory health insurance with 6.7 million enrollees, we identified patients who were newly diagnosed with DLBCL between 2011 and 2018 (index date). Treatment lines were identified based on a predefined set of medication. HCRU and related costs were collected for the entire post index period and per treatment line. Results: A total of 2495 incident DLBCL patients were eligible for the analysis. The average follow-up time after index was 41.7 months. During follow-up, 1991 patients started a first-line treatment, 868 a second-line treatment, and 354 a third-line treatment. Overall, patients spent on average (SD) 5.24 (6.17) days per month in hospital after index. While on anti-cancer treatment, this number increased to nine (10.9) in first-line, 8.7 (13.7) in second-line, and 9.4 (15.8) in third-line treatments. Overall costs per patient per month (PPPM) increased from €421 (875.70) before to €3695 (4652) after index. While on a treatment line, PPPM costs were €17,170 (10,246) in first-line, €13,362 (12,685) in second-line, and €12,112 (16,173) in third-line treatments. Time-unadjusted absolute costs sum up to €59,868 (43,331), €35,870 (37,387), and €28,832 (40,540) during first-line, second-line, and third-line treatments, respectively. The main cost drivers were hospitalizations (71% of total costs) and drug acquisition costs (18% of total costs). Conclusions: The financial burden of DLBCL in Germany is high, mainly due to hospitalization and drug costs. Therefore, there is a high medical need for new cost-effective therapeutic options that can lower the disease burden and remain financially viable to support the growing number of patients with this aggressive disease.
- Published
- 2023
- Full Text
- View/download PDF
14. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
- Author
-
Garcia-Marquez, Maria A., Thelen, Martin, Reinke, Sarah, Keller, Diandra, Wennhold, Kerstin, Lehmann, Jonas, Veldman, Johanna, Borchmann, Sven, Rosenwald, Andreas, Sasse, Stephanie, Diepstra, Arjan, Borchmann, Peter, Engert, Andreas, Klapper, Wolfram, von Bergwelt-Baildon, Michael, Bröckelmann, Paul J., and Schlößer, Hans A.
- Abstract
While classical Hodgkin lymphoma (HL) is highly susceptible to anti-programmed death protein 1 (PD1) antibodies, the exact modes of action remain controversial. To elucidate the circulating lymphocyte phenotype and systemic effects during anti-PD1 1st-line HL treatment we applied multicolor flow cytometry, FluoroSpot and NanoString to sequential samples of 81 HL patients from the NIVAHL trial (NCT03004833) compared to healthy controls. HL patients showed a decreased CD4 T-cell fraction, a higher percentage of effector-memory T cells and higher expression of activation markers at baseline. Strikingly, and in contrast to solid cancers, expression for 10 out of 16 analyzed co-inhibitory molecules on T cells (e.g., PD1, LAG3, Tim3) was higher in HL. Overall, we observed a sustained decrease of the exhausted T-cell phenotype during anti-PD1 treatment. FluoroSpot of 42.3% of patients revealed T-cell responses against ≥1 of five analyzed tumor-associated antigens. Importantly, these responses were more frequently observed in samples from patients with early excellent response to anti-PD1 therapy. In summary, an initially exhausted lymphocyte phenotype rapidly reverted during anti-PD1 1st-line treatment. The frequently observed IFN-y responses against shared tumor-associated antigens indicate T-cell-mediated cytotoxicity and could represent an important resource for immune monitoring and cellular therapy of HL.
- Published
- 2022
- Full Text
- View/download PDF
15. Control of material flow using measuring methods for wrinkle and crack detection during rotary draw bending
- Author
-
Borchmann, Linda, Heftrich, Christopher, Knoche, Jonas, Schiller, Michael, and Engel, Bernd
- Abstract
Until now, rotary draw bending processes have been made error-free by adjustment attempts by experienced machine operators. If corrections are made to prevent wrinkles, there is a risk that the process will lead to cracking. This paper presents a fuzzy controller that independently prevents wrinkling during the tube bending process. Furthermore, measurement methods for crack detection are presented, which will also be integrated into a controller in the next step. The aim is to develop a multi-criteria controller that takes into account quality characteristics such as wrinkling, cracking, spring back and profile elongation.
- Published
- 2023
- Full Text
- View/download PDF
16. Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma
- Author
-
Borchmann, Sven
- Abstract
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma that has traditionally been considered a subgroup of Hodgkin lymphoma. However, morphology, surface marker expression, genetics, and clinical course are different from classic Hodgkin lymphoma. While most patients experience indolent disease with slow progression, some patients can also have more aggressive disease. Nevertheless, outcomes are excellent, and excess mortality due to NLPHL is at most very low. The treatment of newly diagnosed NLPHL has historically mirrored that of classic Hodgkin lymphoma. However, evidence for deviations from that approach has emerged over time and is discussed herein. Less evidence is available for the optimal management of relapsed patients. So-called variant histology has recently emerged as a biological risk factor, providing at least a partial explanation for the observed heterogeneity of NLPHL. Considering variant histology together with other risk factors and careful observation of the clinical course of the disease in each patient can help to assess individual disease aggressiveness. Also important in this mostly indolent disease are the preferences of the patient and host factors, such as individual susceptibility to specific treatment side effects. Considering all this together can guide individualized treatment recommendations, which are paramount in this rare disease.
- Published
- 2022
- Full Text
- View/download PDF
17. Das Hodgkin-Lymphom in fortgeschrittenen Stadien
- Author
-
Ferdinandus, J., Oertel, M., Eichenauer, D. A., Meissner, J., Engert, A., and Borchmann, P.
- Abstract
Hintergrund: Sowohl gemäß der Positronenemissionstomographie (PET-)adaptierte Protokolle als auch neue Substanzen haben in den letzten Jahren Einzug in die Erstlinientherapie des fortgeschrittenen Hodgkin-Lymphoms (HL) gehalten. Ziel der Arbeit: Diese Arbeit gibt eine Übersicht über die leitliniengerechte Therapie des HL in fortgeschrittenen Stadien und aktuelle Studiendaten. Material und Methoden: Es handelt sich um eine narrative Übersichtsarbeit. Ergebnisse: Standardtherapie für Patient*innen bis 60 Jahre mit fortgeschrittenem HL ist eine PET-2-gesteuerte (PET nach 2 Zyklen) Chemotherapie mit 4 Zyklen eBEACOPP (Bleomycin, Etoposid, Doxorubicin, Cyclophosphamid, Vincristin, Procarbazin und Prednison) für PET-2-negative und 6 Zyklen eBEACOPP für PET-2-positive Patient*innen. Diese Therapie hat ein herausragendes Nutzen-Risiko-Verhältnis mit bestmöglicher Lymphomkontrolle, hoher Sicherheit und, für die Mehrheit der Patient*innen, kurzer Therapiedauer von nur 3 Monaten. Patient*innen mit PET-positiven Restbefunden sollen konsolidierend mit 30 Gy bestrahlt werden. Für ältere Patient*innen wird eine Therapie mit 2 Zyklen ABVD (Adriamycin, Bleomycin, Vinblastin und Dacarbazin) mit anschließender Gabe von 4 Zyklen AVD und einer Bestrahlung PET-positiver Reste empfohlen. Schlussfolgerung: Das HL in fortgeschrittenen Stadien ist in mehr als 90 % der Fälle heilbar. Ziel aktueller Studien ist die weitere individualisierte Reduktion der Toxizität bei Erhalt der Effektivität unter Einbindung von Immuncheckpointinhibitoren.
- Published
- 2022
- Full Text
- View/download PDF
18. Erkrankungs- und therapiebedingte Spätfolgen beim Hodgkin-Lymphom
- Author
-
Behringer, K., Oertel, M., Rüffer, J. U., and Borchmann, P.
- Abstract
Hintergrund: Angesichts eindrucksvoller Remissionsraten in den letzten Jahren in der Therapie des Hodgkin-Lymphoms (HL) erlangen späte Folgen nach Diagnose und Therapie einen zunehmenden Stellenwert. Ziel der Arbeit: Späte Folgen nach HL-Behandlung sollten bekannt sein, frühzeitig festgestellt und behandelt werden. Umfassende Betreuung sollte den ehemaligen Patient*innen auch in der Nachsorgephase angeboten werden. Ergebnisse: Die allgemeine Lebensqualität von HL-Patient*innen ist langfristig niedriger als die von nichterkrankten gleichaltrigen Menschen. Führendes Problem ist die Entwicklung einer „cancer-related fatigue“ (CRF), die lange nach Therapie anhalten kann und ehemalige Patient*innen daran hindert, ihr bisheriges Leben weiterzuführen und an den ursprünglichen Arbeitsplatz zurückzukehren. Zu den weiteren, späten Folgen zählt die Entwicklung von Zweitneoplasien, die ein wesentliches Mortalitätsrisiko für ehemalige Patient*innen eines HL darstellt. Die Organtoxizitäten umfassen kardiale, pulmonale und gonadale Schäden. Letztere sind besonders relevant für junge Patient*innen mit noch nicht abgeschlossener Familienplanung. Vor Einleitung der Therapie soll über die Möglichkeit fertilitätserhaltender Maßnahmen aufgeklärt werden. Schlussfolgerung: Im Hinblick auf die anhaltende Beeinträchtigung der Lebensqualität und die negativen Auswirkungen von CRF auf die Beschäftigung von ehemaligen HL-Patient*innen sollten Modelle für eine gezielte Betreuung während der Therapie und in der Nachsorgephase dringend weiterentwickelt werden. Außerdem zielen die Therapiestrategien aktueller klinischer Studien auf eine Reduktion von therapiebedingen späten Folgen bei gleichzeitiger Beibehaltung der guten Tumorkontrolle.
- Published
- 2022
- Full Text
- View/download PDF
19. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
- Author
-
Jaeger, Ulrich, Tam, Constantine S., Borchmann, Peter, McGuirk, Joseph P., Johansen, Marianne, Waller, Edmund K., Jaglowski, Samantha, Andreadis, Charalambos, Foley, Stephen R., Westin, Jason R., Fleury, Isabelle, Ho, P. Joy, Mielke, Stephan, Teshima, Takanori, Salles, Gilles, Schuster, Stephen J., He, Fiona, Maziarz, Richard T., Mayer, Sebastian, Makita, Shinichi, Kersten, Marie J., Ghosh, Monalisa, Wagner-Johnston, Nina, Kato, Koji, Corradini, Paolo, Goto, Hideki, Colicino, Silvia, Agarwal, Abhijit, Lobetti-Bodoni, Chiara, and Bishop, Michael R.
- Published
- 2022
- Full Text
- View/download PDF
20. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
- Author
-
Bethge, Wolfgang A., Martus, Peter, Schmitt, Michael, Holtick, Udo, Subklewe, Marion, von Tresckow, Bastian, Ayuk, Francis, Wagner-Drouet, Eva Marie, Wulf, Gerald G., Marks, Reinhard, Penack, Olaf, Schnetzke, Ulf, Koenecke, Christian, von Bonin, Malte, Stelljes, Matthias, Glass, Bertram, Baldus, Claudia D., Vucinic, Vladan, Mougiakakos, Dimitrios, Topp, Max, Fante, Matthias A., Schroers, Roland, Bayir, Lale, Borchmann, Peter, Buecklein, Veit, Hasenkamp, Justin, Hanoun, Christine, Thomas, Simone, Beelen, Dietrich W., Lengerke, Claudia, Kroeger, Nicolaus, and Dreger, Peter
- Abstract
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). Here, we report the first German real-world data on SOC CAR T-cell therapies with the aim to explore risk factors associated with outcomes. Patients who received SOC axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) for LBCL and were registered with the German Registry for Stem Cell Transplantation (DRST) were eligible. The main outcomes analyzed were toxicities, response, overall survival (OS), and progression-free survival (PFS). We report 356 patients who received axi-cel (n = 173) or tisa-cel (n = 183) between November 2018 and April 2021 at 21 German centers. Whereas the axi-cel and tisa-cel cohorts were comparable for age, sex, lactate dehydrogenase (LDH), international prognostic index (IPI), and pretreatment, the tisa-cel group comprised significantly more patients with poor performance status, ineligibility for ZUMA-1, and the need for bridging, respectively. With a median follow-up of 11 months, Kaplan-Meier estimates of OS, PFS, and nonrelapse mortality (NRM) 12 months after dosing were 52%, 30%, and 6%, respectively. While NRM was largely driven by infections subsequent to prolonged neutropenia and/or severe neurotoxicity and significantly higher with axi-cel, significant risk factors for PFS on the multivariate analysis included bridging failure, elevated LDH, age, and tisa-cel use. In conclusion, this study suggests that important outcome determinants of CD19-directed CAR T-cell treatment of LBCL in the real-world setting are bridging success, CAR-T product selection, LDH, and the absence of prolonged neutropenia and/or severe neurotoxicity. These findings may have implications for designing risk-adapted CAR T-cell therapy strategies.
- Published
- 2022
- Full Text
- View/download PDF
21. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
- Author
-
Reinke, Sarah, Bröckelmann, Paul J., Iaccarino, Ingram, Garcia-Marquez, Maria, Borchmann, Sven, Jochims, Franziska, Kotrova, Michaela, Pal, Karol, Brüggemann, Monika, Hartmann, Elena, Sasse, Stephanie, Kobe, Carsten, Mathas, Stephan, Soekler, Martin, Keller, Ulrich, Bormann, Matthias, Zimmermann, Andreas, Richter, Julia, Fuchs, Michael, von Tresckow, Bastian, Borchmann, Peter, Schlößer, Hans, von Bergwelt-Baildon, Michael, Rosenwald, Andreas, Engert, Andreas, and Klapper, Wolfram
- Abstract
Classic Hodgkin lymphoma (cHL) is the cancer type most susceptible to antibodies targeting programmed cell death protein 1 (PD1) and is characterized by scarce Hodgkin and Reed-Sternberg cells (HRSCs), perpetuating a unique tumor microenvironment (TME). Although anti-PD1 effects appear to be largely mediated by cytotoxic CD8+T cells in solid tumors, HRSCs frequently lack major histocompatibility complex expression, and the mechanism of anti-PD1 efficacy in cHL is unclear. Rapid clinical responses and high interim complete response rates to anti-PD1 based first-line treatment were recently reported for patients with early-stage unfavorable cHL treated in the German Hodgkin Study Group phase 2 NIVAHL trial. To investigate the mechanisms underlying this very early response to anti-PD1 treatment, we analyzed paired biopsies and blood samples obtained from NIVAHL patients before and during the first days of nivolumab first-line cHL therapy. Mirroring the rapid clinical response, HRSCs had disappeared from the tissue within days after the first nivolumab application. The TME already shows a reduction in type 1 regulatory T cells and PD-L1+tumor-associated macrophages at this early time point of treatment. Interestingly, a cytotoxic immune response and a clonal T-cell expansion were not observed in the tumors or peripheral blood. These early changes in the TME were distinct from alterations found in a separate set of cHL biopsies at relapse during anti-PD1 therapy. We identify a unique very early histologic response pattern to anti-PD1 therapy in cHL that is suggestive of withdrawal of prosurvival factors, rather than induction of an adaptive antitumor immune response, as the main mechanism of action.
- Published
- 2020
- Full Text
- View/download PDF
22. SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma
- Author
-
Malin, Jakob J., Di Cristanziano, Veronica, Horn, Carola, Pracht, Elisabeth, Garcia Borrega, Jorge, Heger, Eva, Knops, Elena, Kaiser, Rolf, Böll, Boris, Lehmann, Clara, Jung, Norma, Borchmann, Peter, Fätkenheuer, Gerd, Klein, Florian, Hallek, Michael, and Rybniker, Jan
- Published
- 2022
- Full Text
- View/download PDF
23. Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
- Author
-
Lang, Katharina M, Bereczky, Tamás, Geissler, Jan, Bolanos, Natacha, Morgan, Kathryn E., Plate, Ananda, Vallejo, Ana, Wintrich, Sophie, York, Nick, Loffelhardt, Peter, Huntly, Brian, Sonneveld, Pieter, Boccadoro, Mario, Santini, Valeria, Pospíšilová, Šárka, Hochhaus, Andreas, Barbui, Tiziano, Borchmann, Peter, Buske, Christian, Guillevic, Yann, Calado, Frederico, Harrison, Katy, Dawoud, Dalia, Sanz, Guillermo, Hernández, Jesús María, De Waal, Ellen, Barbus, Martje, Schulze-Rath, Renate, and Bullinger, Lars
- Published
- 2022
- Full Text
- View/download PDF
24. Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
- Author
-
Johnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash, and Timmerman, John
- Published
- 2022
- Full Text
- View/download PDF
25. Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment
- Author
-
Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tsoran-Rosenthal, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, West, Rachel Marceau, Pillai, Pallavi, Nahar, Akash, and Herrera, Alex F.
- Published
- 2022
- Full Text
- View/download PDF
26. Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Author
-
Holzer, Tatjana, Biedermann, Stefanie, Herfort, Inga, Friedrichs, Birte, Holtkamp, Silke, Hanssens, Linda, Assenmacher, Mario, Bethke, Ulf, Schneider, Dina, Miltenyi, Stefan, Overstijns, Toon, Schmid, Christoph, Ayuk, Francis A., Scheid, Christoph, Jühling, Anja, Holtick, Udo, Gödel, Philipp, Borchmann, Peter, and Bürger, Iris
- Published
- 2022
- Full Text
- View/download PDF
27. Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
- Author
-
Borchmann, Peter, Moccia, Alden, Greil, Richard, Hertzberg, Mark, Schaub, Valdete, Hüttmann, Andreas, Keil, Felix, Dierlamm, Judith, Haenel, Mathias, Novak, Urban, Meissner, Julia, Zimmermann, Andreas, Mathas, Stephan, Zijlstra, Josée M., Fosså, Alexander, Viardot, Andreas, Hertenstein, Bernd, Martin, Sonja, Giri, Pratyush, Kamper, Peter, Molin, Daniel, Kreissl, Stefanie, Fuchs, Michael, Schneider, Gundolf, Rosenwald, Andreas, Klapper, Wolfram, Eich, Hans, Baues, Christian, Hallek, Michael, Dietlein, Markus, Kobe, Carsten, Diehl, Volker, and Engert, Andreas
- Published
- 2022
- Full Text
- View/download PDF
28. Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
- Author
-
Bröckelmann, Paul J, Bühnen, Ina, Meissner, Julia, Trautmann-Grill, Karolin, Herhaus, Peter, Halbsguth, Teresa V, Schaub, Valdete, Kerkhoff, Andrea, Mathas, Stephan, Bormann, Matthias, Dickhut, Andreas, Kaul, Helen, Fuchs, Michael, Kobe, Carsten, Baues, Christian, Borchmann, Peter, Engert, Andreas, and von Tresckow, Bastian
- Published
- 2022
- Full Text
- View/download PDF
29. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
- Author
-
Thudium Mueller, Karen, Grupp, Stephan A., Maude, Shannon L., Levine, John E., Pulsipher, Michael A., Boyer, Michael W., August, Keith J., Myers, G. Doug, Tam, Constantine S., Jaeger, Ulrich, Foley, Stephen Ronan, Borchmann, Peter, Schuster, Stephen J., Waller, Edmund K., Awasthi, Rakesh, Potthoff, Bernd, Warren, Andy, Waldron, Edward R., McBlane, Fraser, Chassot-Agostinho, Andrea, and Laetsch, Theodore W.
- Abstract
Tisagenlecleucel is indicated for pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL). The tisagenlecleucel chimeric antigen receptor (CAR) contains a murine single-chain variable fragment domain; we examined the effects of humoral and cellular immune responses to tisagenlecleucel on clinical outcomes using 2 validated assays. Data were pooled from the ELIANA (registered at www.clinicaltrials.govas #NCT02435849) and ENSIGN (#NCT02228096) trials in r/r B-ALL (N = 143) and the JULIET trial (#NCT02445248) in r/r DLBCL (N = 115). Humoral responses were determined by flow cytometric measurement of anti-murine CAR19 (mCAR19) antibodies in serum. Cellular responses were determined using T-cell production of interferon-γ in response to 2 different pools of mCAR19 peptides. Pretreatment anti-mCAR19 antibodies were detected in 81% of patients with r/r B-ALL and 94% of patients with r/r DLBCL. Posttreatment anti-mCAR19 antibodies were higher than patient-specific baseline in 42% of r/r B-ALL and 9% of r/r DLBCL patients. Pretreatment and posttreatment anti-mCAR19 antibodies did not affect tisagenlecleucel cellular kinetics, including maximum concentration and persistence (r2< 0.05), clinical response (day-28 response, duration of response, and event-free survival), and safety. T-cell responses were consistent over time, with net responses <1% at baseline and posttreatment time points in a majority of patients and no effect on transgene expansion or persistence or outcomes. Presence of baseline and/or posttreatment anti-mCAR19 antibodies or T-cell responses did not alter the activity of tisagenlecleucel in patients with r/r B-ALL or r/r DLBCL.
- Published
- 2021
- Full Text
- View/download PDF
30. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
- Author
-
Kreissl, Stefanie, Goergen, Helen, Buehnen, Ina, Kobe, Carsten, Moccia, Alden, Greil, Richard, Eichenauer, Dennis A, Zijlstra, Josée M, Markova, Jana, Meissner, Julia, Feuring-Buske, Michaela, Soekler, Martin, Beck, Hans-Joachim, Willenbacher, Wolfgang, Ludwig, Wolf-Dieter, Pabst, Thomas, Topp, Max S, Hitz, Felicitas, Bentz, Martin, Keller, Ulrich Bernd, Kühnhardt, Dagmar, Ostermann, Helmut, Hertenstein, Bernd, Aulitzky, Walter, Maschmeyer, Georg, Vieler, Tom, Eich, Hans, Baues, Christian, Stein, Harald, Fuchs, Michael, Diehl, Volker, Dietlein, Markus, Engert, Andreas, and Borchmann, Peter
- Abstract
The German Hodgkin Study Group's HD18 trial established the safety and efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) for the treatment of advanced-stage Hodgkin lymphoma. However, because of a protocol amendment during the enrolment period (June 1, 2011) that changed standard treatment from eight to six cycles, the results of the HD18 trial have been partially immature. We report a prespecified 5-year follow-up analysis of the completed HD18 trial.
- Published
- 2021
- Full Text
- View/download PDF
31. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
- Author
-
Azoulay, Élie, Castro, Pedro, Maamar, Adel, Metaxa, Victoria, de Moraes, Alice Gallo, Voigt, Louis, Wallet, Florent, Klouche, Kada, Picard, Muriel, Moreau, Anne-Sophie, Van De Louw, Andry, Seguin, Amélie, Mokart, Djamel, Chawla, Sanjay, Leroy, Julien, Böll, Boris, Issa, Nahema, Levy, Bruno, Hemelaar, Pleun, Fernandez, Sara, Munshi, Laveena, Bauer, Philippe, Schellongowski, Peter, Joannidis, Michael, Moreno-Gonzalez, Gabriel, Galstian, Gennadii, Darmon, Michael, Valade, Sandrine, Zafrani, Lara, Mariotte, Eric, Lemiale, Virginie, Arnulf, Bertrand, Boissel, Nicolas, Thieblemont, Catherine, Rabian, Florence, Harel, Stéphanie, Di Blasi, Roberta, Delgado, Julio, Ortiz, Valentin, Blaise, Didier, Fürst, Sabine, Legrand, Faezeh, Chabannon, Christian, Forcade, Edouard, Gros, François-Xavier, Borel, Cécile, Huynh, Anne, Récher, Christian, Rudzki, Jakob, Rakszawski, Kevin, Sesques, Pierre, Bachy, Emmanuel, Salles, Gilles, Perales, Miguel A, Wohlfarth, Philipp, Staudingert, Thomas, Jäger, Ulrich, Cartron, Guillaume, Fégueux, Nathalie, Ceballos, Patrice, Platon, Laura, Gastinne, Thomas, Tessoulin, Benoit, Le Bourgeois, Amandine, Gavrilina, Olga, Sureda, Anna, Mussetti, Alberto, Borrega, Jorge Garcia, Borchmann, Peter, Lin, Yi, Benjamin, Reuben, de Guibert, Sophie, Quelven, Quentin, Yakoub-Agha, Ibrahim, Beauvais, David, and Rubio, Marie-Therese
- Abstract
Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of this study was to describe management of critically ill CAR T-cell recipients in intensive care.
- Published
- 2021
- Full Text
- View/download PDF
32. Ergebnisse der PET-adaptierten Phase-III-Studie HD21 der deutschen Hodgkin Studiengruppe (GHSG)
- Author
-
Kobe, C., Dietlein, M., Schneider, G., Fuchs, M., Kreissl, S., Ferdinandus, J., Eich, H., Baues, C., Hallek, M., Diehl, V., and Borchmann, P.
- Published
- 2024
- Full Text
- View/download PDF
33. Baseline Metabolic Tumour Volume (MTV) as prognostic marker for forecasting Chemotherapy Outcome in Early-Stage Unfavourable Hodgkin Lymphoma: Data from the Phase III HD17 Trial
- Author
-
Roth, K., van Heek, L., Weindler, J., Gorniak, C., Kaul, H., Müller, H., Mettler, J., Baues, C., Fuchs, M., Borchmann, P., Ferdinandus, J., Dietlein, M., Voltin, C. A., and Kobe, C.
- Published
- 2024
- Full Text
- View/download PDF
34. Evaluating GPT-4's performance in oncologic disease classification based on PET/CT reports of lymphoma patients: Are large language models the long-awaited 'magic bullet'?
- Author
-
Voltin, C., Dietlein, M., Kottlors, J., Borchmann, P., Gödel, P., Bröckelmann, P. J., Drzezga, A., and Dratsch, T.
- Published
- 2024
- Full Text
- View/download PDF
35. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
- Author
-
Borchmann, Sven, Müller, Horst, Haverkamp, Heinz, Baues, Christian, Marková, Jana, Hüttmann, Andreas, Glunz, Axel, Fuchs, Michael, Borchmann, Peter, and Engert, Andreas
- Abstract
The majority of patients with Hodgkin Lymphoma (HL) can be cured with stage and risk adapted treatment today. Therefore, current research focuses on reducing long-term sequelae of treatment. Osteonecrosis (ON) is a severe long-term complication of HL treatment which has so far not been systematically evaluated. Hence, we investigated incidence, risk factors and timing of symptomatic ON in HL patients. Further endpoints included localization, intervention and outcome of ON. We included all qualified HL patients of the randomized German Hodgkin Study Group trials HD10-15 and HD18, recruited between 05/1998 and 07/2014 and aged from 16 to 60 years. Among 11 330 patients, 66 developed symptomatic ON after first-line treatment, 83.3% within three years. The incidence of symptomatic ON was 0.2% in early-stage HL and 1.0% in advanced-stage HL. Logistic regression revealed the total cumulative corticosteroid dose to be a strong risk factor interacting with younger age. Male sex additionally increased the risk of symptomatic ON. The prognostic value of the corresponding logistic regression model was rather high (AUC = 0.78). Other tested potential risk factors including obesity, IPS and radiotherapy did not further increase the risk of ON. Further development of current treatment protocols should aim to reduce the cumulative corticosteroid dose.
- Published
- 2019
- Full Text
- View/download PDF
36. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)
- Author
-
Gillessen, Sarah, Plütschow, Annette, Fuchs, Michael, Markova, Jana, Greil, Richard, Topp, Max S, Meissner, Julia, Zijlstra, Josée M, Eichenauer, Dennis A, Bröckelmann, Paul J, Diehl, Volker, Borchmann, Peter, Engert, Andreas, and von Tresckow, Bastian
- Abstract
To improve the long-term tumour control in early, unfavourable Hodgkin Lymphoma, the German Hodgkin Study Group (GHSG) HD14 trial compared four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with an intensified chemotherapy regimen consisting of two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escalated BEACOPP) plus two cycles of ABVD. The final analysis of the trial showed a significant advantage in terms of freedom from treatment failure (difference 7·2% [95% CI 3·8–10·5] at 5 years) for patients who received two cycles of escalated BEACOPP and two cycles of ABVD. However, there was no difference in overall survival between the two groups. To evaluate long-term efficacy and toxicity of this strategy, we did a follow-up analysis.
- Published
- 2021
- Full Text
- View/download PDF
37. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial
- Author
-
Frontzek, Fabian, Ziepert, Marita, Nickelsen, Maike, Altmann, Bettina, Glass, Bertram, Haenel, Mathias, Truemper, Lorenz, Held, Gerhard, Bentz, Martin, Borchmann, Peter, Dreyling, Martin, Viardot, Andreas, Kroschinsky, Frank P, Metzner, Bernd, Staiger, Annette M, Horn, Heike, Ott, German, Rosenwald, Andreas, Loeffler, Markus, Lenz, Georg, and Schmitz, Norbert
- Abstract
R-MegaCHOEP was the first phase 3 study comparing high-dose chemotherapy plus rituximab followed by autologous haematopoietic stem-cell transplantation (HSCT) with conventional chemotherapy plus rituximab in first-line therapy for patients aged 60 years or younger with high-risk aggressive B-cell lymphoma. Little is known about the long-term outcomes of these patients. We aimed to evaluate the long-term efficacy and safety of conventional chemotherapy versus high-dose chemotherapy after 10 years of follow-up in the R-MegaCHOEP trial.
- Published
- 2021
- Full Text
- View/download PDF
38. Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
- Author
-
Jachimowicz, Ron D., Klapper, Wolfram, Glehr, Gunther, Müller, Horst, Haverkamp, Heinz, Thorns, Christoph, Hansmann, Martin Leo, Möller, Peter, Stein, Harald, Rehberg, Thorsten, von Tresckow, Bastian, Reinhardt, H. C., Borchmann, Peter, Chan, Fong Chun, Spang, Rainer, Scott, David W., Engert, Andreas, Steidl, Christian, Altenbuchinger, Michael, and Rosenwald, Andreas
- Published
- 2021
- Full Text
- View/download PDF
39. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis
- Author
-
Bröckelmann, Paul J., Müller, Horst, Gillessen, Sarah, Yang, Xiaoqin, Koeppel, Larissa, Pilz, Veronika, Marinello, Patricia, Kaskel, Peter, Raut, Monika, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, and von Tresckow, Bastian
- Abstract
To evaluate patterns of rrHL after contemporary first-line treatment we studied 409 patients with first rrHL (HD13: n= 87, HD14: n= 118, HD15: n= 188, HDR3i: n= 51) at a median age of 37.4 years (18.4–76.8) from the GHSG database. Time to first relapse was ≤12 months in 49% and stage III/IV rrHL present in 52% of patients. In total, 291 patients received high-dose chemotherapy and autologous stem-cell transplantation (ASCT) and intended ASCT failed in 38 patients. ASCT was primarily not intended in 80 patients largely due to low risk disease or age/comorbidities. Overall, 10-year progression-free (PFS) and overall survival (OS) rates after first relapse were 48.2% (95% CI 41.9–54.2%) and 59.4% (95% CI 53.0–65.2%), respectively, with significant differences between subgroups. Inferior survival was observed with no ASCT due to advanced age/comorbidities (five-year PFS 36.2%, 95% CI 17.7–55.0%) or failure of salvage therapy (five-year PFS 36.3%, 95% CI 19.7–53.2%). Similarly, presence of primary refractory disease or stage IV at rrHL conferred inferior survival. In patients with low-risk disease, however, survival appeared favorable even without ASCT (10 y PFS 72.6%, 95% CI 53.7–84.8%). We herein confirm the curative potential of current rrHL treatments providing a robust benchmark to evaluate novel therapeutic strategies in rrHL. Approximately 50% of rrHL patients experienced a consecutive relapse.
- Published
- 2021
- Full Text
- View/download PDF
40. Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing
- Author
-
Heger, Jan-Michel, Mattlener, Julia, Gödel, Philipp, Balke-Want, Hyatt, Sieg, Noëlle, Kutsch, Nadine, Becker, Kerstin, Weiss, Jonathan, Reinhardt, H. Christian, Hallek, Michael, Borchmann, Peter, von Tresckow, Bastian, and Borchmann, Sven
- Published
- 2022
- Full Text
- View/download PDF
41. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy
- Author
-
Montesinos-Rongen, Manuel, Brunn, Anna, Tuchscherer, Armin, Borchmann, Peter, Schorb, Elisabeth, Kasenda, Benjamin, Altmüller, Janine, Illerhaus, Gerald, Ruge, Maximilian I., Maarouf, Mohammad, Büttner, Reinhard, Hansmann, Martin-Leo, Hallek, Michael, Prinz, Marco, Siebert, Reiner, and Deckert, Martina
- Abstract
In newly diagnosed systemic diffuse large B-cell lymphoma, next-generation sequencing of plasma-derived cell-free DNA (cfDNA) detects somatic mutations as accurate as genotyping of the tumor biopsy. A distinct diffuse large B-cell lymphoma entity confined to the central nervous system is primary central nervous system lymphoma (PCNSL), which requires intracerebral biopsy and neuropathologic analysis to establish the diagnosis. So far, a biomarker for diagnosis and follow-up of PCNSL that can be investigated in blood has not been identified. This article addresses the question whether somatic mutations of the CD79Band MYD88driver genes of PCNSL can be detected in cfDNA at disease diagnosis. Stereotactic biopsies and cfDNA of 27 PCNSL patients were analyzed for CD79B and MYD88 mutations. As control, cfDNA derived from six healthy volunteers was used. CD79B and MYD88 hot spot mutations were identified in 16 of 27 (59%) and 23 of 27 (85%) PCNSL biopsies, respectively, but only in 0 of 27 (0%) and 1 of 27 (4%) corresponding cfDNA samples, respectively. In cfDNA of one of four patients with Waldenstrom disease, as a further control, the MYD88 L265P mutation was readily detected, despite complete clinical remission. These data suggest that in PCNSL even if they carry such mutations, alterations of CD79B and MYD88 cannot be reliably detected in blood-derived cfDNA obtained before intracerebral biopsy.
- Published
- 2020
- Full Text
- View/download PDF
42. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
- Author
-
Bröckelmann, Paul J., Goergen, Helen, Keller, Ulrich, Meissner, Julia, Ordemann, Rainer, Halbsguth, Teresa V., Sasse, Stephanie, Sökler, Martin, Kerkhoff, Andrea, Mathas, Stephan, Hüttmann, Andreas, Bormann, Matthias, Zimmermann, Andreas, Mettler, Jasmin, Fuchs, Michael, von Tresckow, Bastian, Baues, Christian, Rosenwald, Andreas, Klapper, Wolfram, Kobe, Carsten, Borchmann, Peter, and Engert, Andreas
- Abstract
IMPORTANCE: In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects. Nivolumab is well tolerated and highly effective in relapsed/refractory cHL but has not been adequately studied in first-line treatment of early-stage cHL. The NIVAHL trial evaluated nivolumab in this setting with the aim to develop a highly effective yet tolerable systemic therapy to ultimately mitigate morbidity in patients who survive cHL. OBJECTIVE: To evaluate efficacy of 2 experimental nivolumab-based first-line treatment strategies in patients with early-stage unfavorable cHL. DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, multicenter, phase 2 randomized clinical trial, open between April 2017 and October 2018. The trial took place at 35 trial centers across Germany, ranging from academic centers to private offices. Eligibility was defined by age 18 to 60 years, cHL confirmed by expert pathology review, early-stage unfavorable disease by German Hodgkin Study Group criteria (stage I to II with risk factor[s]), and absence of serious concomitant disease or organ dysfunction. Among 110 enrolled patients, 109 were eligible. INTERVENTIONS: Systemic therapy, per random assignment (1:1) to either concomitant treatment with 4 cycles of nivolumab and doxorubicin, vinblastine, and dacarbazine (N-AVD) or sequential treatment with 4 doses of nivolumab, 2 cycles of N-AVD, and 2 cycles of AVD at standard doses, followed by 30-Gy involved-site radiotherapy. MAIN OUTCOMES AND MEASURES: Complete remission (CR) rate after study treatment, aiming at excluding a CR rate of 80% or lower via a 2-sided 95% CI for each treatment group. RESULTS: Of 109 patients included in this study, 65 (59.6%) were women, and the median (range) age was 27 (18-60) years. At interim staging after 2 cycles of N-AVD or 4 doses of nivolumab monotherapy, 54 of 54 (100%) and 49 of 51 (96%) response-eligible patients, respectively, achieved an objective response, with CR in 47 (87%) and 26 (51%) patients, respectively. Among 101 patients eligible for primary end point analysis, 46 of 51 (90%; 95% CI, 79%-97%) patients receiving concomitant therapy and 47 of 50 (94%; 95% CI, 84%-99%) patients receiving sequential therapy achieved CR after study treatment. With a median follow-up of 13 months, 12-month progression-free survival was 100% for patients receiving concomitant treatment and 98% (95% CI, 95%-100%) for patients receiving sequential therapy. CONCLUSIONS AND RELEVANCE: Both strategies combining nivolumab and AVD are feasible and resulted in high remission rates. Despite narrowly missing the efficacy benchmark in the concomitant group, the excellent 12-month progression-free survival and the unexpectedly high CR rate after 4 doses of nivolumab monotherapy warrant further evaluation of this approach in the first-line treatment of patients with early-stage cHL. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03004833
- Published
- 2020
- Full Text
- View/download PDF
43. Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
- Author
-
Eichenauer, Dennis A., Plütschow, Annette, Fuchs, Michael, Hartmann, Sylvia, Hansmann, Martin-Leo, Böll, Boris, von Tresckow, Bastian, Borchmann, Peter, and Engert, Andreas
- Published
- 2020
- Full Text
- View/download PDF
44. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
- Author
-
Maziarz, Richard T., Waller, Edmund K., Jaeger, Ulrich, Fleury, Isabelle, McGuirk, Joseph, Holte, Harald, Jaglowski, Samantha, Schuster, Stephen J., Bishop, Michael R., Westin, Jason R., Mielke, Stephan, Teshima, Takanori, Bachanova, Veronika, Foley, Stephen R., Borchmann, Peter, Salles, Gilles A., Zhang, Jie, Tiwari, Ranjan, Pacaud, Lida B., Ma, Qiufei, and Tam, Constantine S.
- Abstract
The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19.3 months among patients infused with a single dose of tisagenlecleucel. Patients enrolled were ≥18 years of age with r/r DLBCL after ≥2 lines of therapy and had either undergone a failed autologous stem cell transplant or were ineligible for the procedure. Two validated HRQoL instruments, Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and Short Form-36 (SF-36) Health Survey, were used to measure HRQoL at baseline and months 3, 6, 12, and 18. At data cutoff (21 May 2018), 115 patients had received tisagenlecleucel infusion. Among the 99 patients evaluated, overall response rate was 54%, and 40% of patients achieved complete response (CR). Initially, 108 patients completed the HRQoL assessments at baseline, including 57 patients who eventually achieved CR or partial response (PR). Further, 30 and 21 patients in clinical response who completed assessments at baseline also completed assessments at months 12 and 18, respectively. Patients who achieved CR or PR sustained HRQoL improvement in all FACT scores at all time points. SF-36 instruments showed improvement above the minimal clinically important differences on 5 of 8 subscales. Long-term follow-up in the phase 2 JULIET study demonstrated that patients with r/r DLBCL who respond to tisagenlecleucel therapy had sustained, clinically meaningful improvements in HRQoL. This trial was registered at www.clinicaltrials.gov as #NCT02445248.
- Published
- 2020
- Full Text
- View/download PDF
45. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
- Author
-
Awasthi, Rakesh, Pacaud, Lida, Waldron, Edward, Tam, Constantine S., Jäger, Ulrich, Borchmann, Peter, Jaglowski, Samantha, Foley, Stephen Ronan, van Besien, Koen, Wagner-Johnston, Nina D., Kersten, Marie José, Schuster, Stephen J., Salles, Gilles, Maziarz, Richard T., Anak, Özlem, del Corral, Christopher, Chu, Jufen, Gershgorin, Irina, Pruteanu-Malinici, Iulian, Chakraborty, Abhijit, Mueller, Karen Thudium, and Waller, Edmund K.
- Abstract
The anti-CD19 chimeric antigen receptor (CAR)–T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). We correlated tisagenlecleucel cellular kinetics with clinical/product parameters in 111 patients treated in JULIET. Tisagenlecleucel persistence in responders and nonresponders, respectively, was demonstrated for 554 and 400 days maximum by flow cytometry and for 693 and 374 days maximum by quantitative polymerase chain reaction (qPCR). No relationships were identified between cellular kinetics (qPCR) and product characteristics, intrinsic/extrinsic factors, dose, or immunogenicity. Most patients with 3-month response had detectable transgene at time of response and continued persistence for ≥6 months. Expansion (maximal expansion of transgene/CAR-positive T-cell levels in vivo postinfusion [Cmax]) was potentially associated with response duration but this did not reach statistical significance (hazard ratio for a twofold increase in Cmax, 0.79; 95% confidence interval, 0.61-1.01). Tisagenlecleucel expansion was associated with cytokine-release syndrome (CRS) severity and tocilizumab use; no relationships were observed with neurologic events. Transgene levels were associated with B-cell levels. Dose was associated with CRS severity, but this was not statistically significant after adjusting for baseline tumor burden. In contrast to the results from B-cell precursor acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia, similar exposure was observed in DLBCL in this study regardless of response and expansion was lower in DLBCL than B-ALL, likely from differences in cancer location and/or T-cell intrinsic factors. Relationships between expansion and CRS severity, and lack of relationships between dose and exposure, were similar between DLBCL and B-ALL. Tisagenlecleucel cellular kinetics in adult relapsed/refractory DLBCL improve current understanding of in vivo expansion and its relationships with safety/efficacy endpoints. This trial was registered at www.clinicaltrials.gov as #NCT02445248.
- Published
- 2020
- Full Text
- View/download PDF
46. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
- Author
-
Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Borchmann, Peter, Viardot, Andreas, Soekler, Martin, Keller, Ulrich, Schmidt, Christian, Truemper, Lorenz, Mahlberg, Rolf, Marks, Reinhard, Hoeffkes, Heinz-Gert, Metzner, Bernd, Dierlamm, Judith, Frickhofen, Norbert, Haenel, Mathias, Neubauer, Andreas, Kneba, Michael, Merli, Francesco, Tucci, Alessandra, de Nully Brown, Peter, Federico, Massimo, Lengfelder, Eva, di Rocco, Alice, Trappe, Ralf, Rosenwald, Andreas, Berdel, Christian, Maisenhoelder, Martin, Shpilberg, Ofer, Amam, Josif, Christofyllakis, Konstantinos, Hartmann, Frank, Murawski, Niels, Stilgenbauer, Stephan, Nickelsen, Maike, Wulf, Gerald, Glass, Bertram, Schmitz, Norbert, Altmann, Bettina, Loeffler, Markus, and Pfreundschuh, Michael
- Abstract
Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. In the FLYER trial, we assessed whether four cycles of CHOP plus six applications of rituximab are non-inferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with favourable prognosis.
- Published
- 2019
- Full Text
- View/download PDF
47. Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
- Author
-
Morschhauser, Franck, Dahiya, Saurabh, Palomba, M. Lia, Martin Garcia-Sancho, Alejandro, Reguera Ortega, Juan Luis, Kuruvilla, John, Jäger, Ulrich, Cartron, Guillaume, Izutsu, Koji, Dreyling, Martin, Kahl, Brad, Ghesquieres, Hervé, Ardeshna, Kirit, Goto, Hideki, Barbui, Anna Maria, Abramson, Jeremy S., Borchmann, Peter, Fleury, Isabelle, Mielke, Stephan, Skarbnik, Alan, de Vos, Sven, Kamdar, Manali, Karmali, Reem, Viardot, Andreas, Farazi, Thalia, Fasan, Omotayo, Lymp, James, Vedal, Min, Nishii, Rina, Avilion, Ariel, Papuga, Jessica, Kumar, Jinender, and Nastoupil, Loretta J.
- Published
- 2024
- Full Text
- View/download PDF
48. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
- Author
-
Bethge, WA, Martus, P, Schmitt, M, Holtick, U, Subklewe, M, von Tresckow, B, Ayuk, F, Wagner-Drouet, EM, Wulf, G, Marks, R, Penack, O, Schnetzke, U, Koenecke, C, von Bonin, M, Stelljes, M, Glass, B, Baldus, CD, Vucinic, V, Mougiakakos, D, Topp, M, Fante, M, Schroers, R, Bayir, L, Borchmann, P, Buecklein, V, Hasenkamp, J, Hanoun, C, Thomas, S, Beelen, D, Lengerke, C, Kroeger, N, and Dreger, P
- Abstract
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as new standard-of-care (SOC) treatment in patients with relapsed/refractory large B-cell lymphoma (LBCL). Here, we report the first German real-world data on SOC CAR-T cell therapies with the aim to explore risk factors associated with outcome.
- Published
- 2024
- Full Text
- View/download PDF
49. TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma
- Author
-
Morschhauser, Franck, Dahiya, Saurabh, Palomba, M. Lia, Martin Garcia-Sancho, Alejandro, Reguera, Juan Luis, Kuruvilla, John, Jaeger, Ulrich, Cartron, Guillaume, Izutsu, Koji, Dreyling, Martin, Kahl, Brad S., Ghesquieres, Herve, Ardeshna, Kirit, Goto, Hideki, Barbui, Anna Maria, Abramson, Jeremy S., Borchmann, Peter, Fleury, Isabelle, Mielke, Stephan, Skarbnik, Alan, de Vos, Sven, Kamdar, Manali, Karmali, Reem, Viardot, Andreas, Farazi, Thalia, Fasan, Omotayo, Lymp, James, Vedal, Min, Nishii, Rina, Avilion, Ariel, Papuga, Jessica, and Nastoupil, Loretta J.
- Abstract
Background: Results with CD19-directed CAR T cell therapy in patients (pts) with second-line (2L) R/R follicular lymphoma (FL) and high-risk features, such as progression of disease within 24 months (POD24) from diagnosis or double refractory to anti-CD20 antibody plus alkylator, have not been previously reported. TRANSCEND FL (NCT04245839), a global, phase 2, open-label, single-arm, multicohort, pivotal study, assessed efficacy and safety of the anti-CD19 CAR T cell therapy lisocabtagene maraleucel (liso-cel) in pts with second line or later (2L+) R/R indolent NHL. Some data from the primary analysis were previously reported, including safety in 2L+ R/R FL, and focused on efficacy in third line or later R/R FL (Morschhauser F, et al. Hematol Oncol2023;41[S2]:877‒880). Here, we report primary analysis results in the cohort of pts with 2L high-risk R/R FL.
- Published
- 2023
- Full Text
- View/download PDF
50. Systematic Literature Review to Identify Influencing Factors of Efficacy and Safety Outcomes of Chimeric Antigen Receptor T-Cell Therapies in Large B-Cell Lymphoma
- Author
-
Heger, Jan-Michel, Jost, Jonas, Riou, Sybille, Walzer, Stefan, Mahlich, Joerg, and Borchmann, Peter
- Abstract
Background:
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.